Compare Hasbro, Inc. (HAS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Pfizer Inc — how do they compare? Hasbro, Inc. trades at $90.96 (market cap $11.53B), while Pfizer Inc trades at $24.94 (market cap $141.06B). The key difference: Pfizer Inc is far larger — about 12.2× Hasbro, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.95%). Which is the better fit depends on your goals.
| HAS | PFE | |
|---|---|---|
Market Cap | $11.53B | $141.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $28.56 |
52-Week Low | $70.95 | $23.29 |
Enterprise Value | $13.80B | $191.72B |
Dividend Yield | 3.44% | 6.95% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $81.56, showing minimal daily movement with a 0.01% gain. The stock exhibits a bearish technical signal, with RSI indicating overbought conditions near-term. Fundamentally, the company reported a net loss of -$322.4M in 2025 despite revenue growth to $4.7B, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights upcoming Q2 2026 earnings and new product launches like Blooms by Play-Doh targeting adult consumers.
The outlook remains mixed with analyst consensus leaning bullish (51.5% buy ratings) and a $104.75 price target suggesting 28% upside. Key risks include persistent negative profit margins, high debt levels, and competitive pressures in the toy industry. Earnings performance on July 21 will be critical for near-term direction.
Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.
The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
